Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
February 24, 2020 09:00 ET
|
Kitov Pharma Ltd.
Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and...
Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results
February 11, 2020 07:00 ET
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
February 03, 2020 08:20 ET
|
Kitov Pharma Ltd.
Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage...
Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors
January 24, 2020 08:10 ET
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
January 09, 2020 08:35 ET
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Announces Closing of FameWave Acquisition
January 08, 2020 07:30 ET
|
Kitov Pharma Ltd.
Concurrent with the close of the transaction, OrbiMed, Pontifax and Arkin are investing $3.5 million in Kitov and will each hold approximately 11% of the company’s shares on a non-diluted...
Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule
January 08, 2020 07:00 ET
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.S
October 11, 2019 08:54 ET
|
Kitov Pharma Ltd.
In the amended agreement with Coeptis, Kitov will receive up to $99.5M in milestone and reimbursement payments plus 20% in royaltiesCoeptis Pharmaceuticals has engaged a distribution partner with an...
Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board
October 02, 2019 08:20 ET
|
Kitov Pharma Ltd.
Appointment of industry leader brings broad R&D Oncology Experience to Board TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a...
Kitov Pharma Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance
September 09, 2019 08:30 ET
|
Kitov Pharma Ltd.
Data validates NT-219 mechanism of action in reversing resistance to various FDA-approved treatments in pancreatic tumor models of mice implanted with biopsies from patients (PDX)...